Also trades as: PFE.DE (XETRA) · $vol 1M · PFE.NE (NEO) · $vol 1M · PFE.F (FSX) · $vol 0M · PFE.BA (BUE) · $vol 0M

$25.90

-0.05 (-0.19%)

Weekly Expected Move ±2.4%

$24 $25 $25 $26 $27

NYSE · Healthcare · Drug Manufacturers - General · Alpha Radar Neutral · Power 51 · $147.6B mcap · 5.69B float · 0.665% daily turnover · Short 39% of daily vol

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue

$62.6B -1.6% ▼

5Y CAGR: +8.5%

Gross Profit

$44.0B +5.2% ▲

5Y CAGR: +8.1%

Operating Income

$15.4B -6.3% ▼

5Y CAGR: +11.2%

Net Income

$7.8B -3.1% ▼

5Y CAGR: -3.2%

EPS (Diluted)

$1.36 -3.5% ▼

5Y CAGR: -3.5%

EBITDA

$15.1B -16.7% ▼

5Y CAGR: +2.8%

Profit Margins

Year-over-Year Growth

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$81.3B	$100.3B	$59.6B	$63.6B	$62.6B
YoY Growth	+95.2%	+23.4%	-40.6%	+6.8%	-1.6%
Cost of Revenue	$34.4B	$38.2B	$29.2B	$21.8B	$18.6B
Gross Profit	$46.9B	$62.1B	$30.3B	$41.8B	$44.0B
Gross Margin	57.7%	61.9%	50.9%	65.8%	70.3%
R&D Expenses	$13.8B	$11.4B	$10.6B	$10.7B	$12.0B
SG&A Expenses	$12.3B	$13.1B	$14.5B	$14.7B	$13.3B
Operating Expenses	$26.1B	$24.5B	$25.0B	$25.4B	$28.6B
Operating Income	$20.8B	$37.5B	$5.3B	$16.5B	$15.4B
Operating Margin	25.6%	37.4%	8.9%	25.9%	24.7%
Interest Expense	$1.3B	$1.2B	$2.2B	$3.1B	$2.7B
Income Before Tax	$24.3B	$34.7B	$1.1B	$8.0B	$7.5B
Tax Expense	$1.9B	$3.3B	-$1.1B	-$28M	-$266M
Net Income	$22.1B	$31.4B	$2.1B	$8.0B	$7.8B
Net Margin	27.2%	31.3%	3.6%	12.6%	12.4%
EPS (Diluted)	$3.88	$5.47	$0.37	$1.41	$1.36
EBITDA	$30.8B	$41.0B	$9.6B	$18.1B	$15.1B
Shares Outstanding	5.71B	5.73B	5.71B	5.70B	5.69B

Line Item	FY2024 Q2	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1
Revenue	$13.3B	$17.7B	$17.8B	$13.7B	$14.7B	$16.7B	$17.6B	$14.5B
Cost of Revenue	$5.0B	$6.9B	$4.8B	$3.9B	$5.2B	$4.2B	$5.3B	$4.7B
Gross Profit	$8.2B	$10.8B	$13.0B	$9.8B	$9.4B	$12.5B	$12.3B	$9.7B
Gross Margin	62.1%	60.8%	73.0%	71.7%	64.3%	74.9%	70.0%	67.3%
R&D Expenses	$2.7B	$2.6B	$3.0B	$2.2B	$2.4B	$3.9B	$3.4B	$2.6B
SG&A Expenses	$3.7B	$3.2B	$4.2B	$3.0B	$3.4B	$3.2B	$3.7B	$3.0B
Operating Expenses	$6.4B	$5.8B	$7.2B	$5.2B	$5.8B	$8.9B	$8.6B	$5.7B
Operating Income	$1.9B	$5.0B	$5.7B	$4.6B	$3.6B	$3.5B	$3.7B	$4.0B
Operating Margin	14.1%	28.1%	32.2%	33.7%	24.4%	21.3%	21.0%	27.9%
Interest Expense	$778M	$783M	$739M	$654M	$654M	$652M	$711M	$668M
Income Before Tax	-$103M	$4.7B	-$10M	$2.8B	$3.0B	$3.3B	-$1.6B	$3.2B
Tax Expense	-$134M	$234M	-$421M	-$189M	$141M	-$216M	-$2M	$461M
Net Income	$24M	$4.5B	$403M	$3.0B	$2.9B	$3.5B	-$1.6B	$2.7B
Net Margin	0.2%	25.3%	2.3%	21.6%	19.9%	21.3%	-9.4%	18.6%
EPS (Diluted)	$0.00	$0.78	$0.07	$0.52	$0.51	$0.62	$-0.29	$0.47
EBITDA	$2.4B	$7.3B	$5.1B	$5.1B	$5.3B	$5.6B	$756M	$5.2B
Shares Outstanding	5.70B	5.71B	5.70B	5.71B	5.71B	5.71B	5.69B	5.73B

PFE NYSE